Skip to main content

Table 6 Dose and infection-type dependent risk of infection in patients treated with eptinezumab vs. Placebo

From: Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment

Eptinezumab dose

Statistics

Infection

Any

Viral

Bacterial

COVID-19

Urinary

Any

p- value

0.717

0.599

0.585

0.604

0.421

RR

1.03

1.04

0.87

1.16

0.81

Clinical

p-value

0.472

0.411

0.699

0.604

0.760

RR

1.06

1.07

0.90

1.16

0.92

High

p- value

0.015

0.038

0.246

0.827

0.439

RR

1.23

1.21

1.37

1.08

1.25

  1. COVID-19 - Coronavirus disease 2019; UTI– urinary tract infection; RR– risk ratio
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us